On Friday, BridgeBio Pharma Inc (BBIO) stock saw a decline, ending the day at $27.33 which represents a decrease of $-0.16 or -0.58% from the prior close of $27.49. The stock opened at $27.84 and ...
GET MORE AI-GENERATED SIGNALS: December 02, 2024, 04:48 am ET, BY Jesse F.- Contributor| Editor: Thomas H. Kee Jr. ( Follow ...
On Monday, BridgeBio Pharma, Inc. (NASDAQ:BBIO) presented initial outcomes from the ATTRibute-CM open-label extension (OLE) ...
Zacks.com on MSN7d
BridgeBio Stock Up on FDA Approval of Cardiovascular DrugBridgeBio Pharma, Inc. BBIO recently announced that it obtained FDA approval for its pipeline candidate acoramidis for the ...
Research analysts at HC Wainwright increased their FY2024 earnings estimates for shares of BridgeBio Pharma in a research ...
On Monday, BridgeBio Pharma Inc (BBIO) stock saw a decline, ending the day at $22.35 which represents a decrease of $-1.37 or -5.78% from the prior close of $23.72. The stock opened at $23.32 and ...
2025 will be a very eventful year for BridgeBio. In addition to the commercial launches of Attruby in the United States, ...
The candidate has been approved under the brand name Attruby. BBIO stock surged on the news. The FDA approval is based on positive results from the phase III ATTRibute-CM study, in which Attruby ...
Zacks.com on MSN4d
Biotech Stock Roundup: BBIO Stock Up on Drug Approval, SAVA, APLT Plunge on Setbacks & MorePipeline and regulatory updates are in focus in the biotech sector. Among these, BridgeBio Pharma, Inc. BBIO gained on ...
Mizuho Securities analyst Salim Syed has maintained their bullish stance on BBIO stock, giving a Buy rating on November 15. Don't Miss our Black Friday Offers: Salim Syed has given his Buy rating ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback